Roughly more than 15 million people suffer from chronic symptoms of rhinosinusitis in the United States, that is, prevalence of chronic rhinosinusitis ranges from 1% to 5% of the total US population. Chronic rhinosinusitis is primarily characterized by nasel blockage, inflammation of the sinus and nasel linings, facial pain along with rhinorrhea and loss of sense of smell. Effective treatment includes improvement in sinus outflow, enhancement of mucociliary clearance and elimination of inflammation and local infection among other associated treatments.
The global Chronic Rhinosinusitis market study covers the current COVID-19 scenario that has turned the global business sphere upside down. The coronavirus has resulted in a major economic downturn worldwide, while also adversely impacting the growth of this industrial sector. The pandemic has brought about drastic changes in market conditions.
Regeneron Pharmaceuticals and Sanofi’s Dupixent (Dupilumab) was approved in June 2019, by US Food and Drug Administration (FDA). This drug is customized for adults with incompetently controlled chronic rhinosinusitis along with nasal polyposis. It offers a lucid picture of current trends in the global market, with an unbiased perspective of the leading market players, key regions/countries, end-use industries, and various product types.
The Chronic Rhinosinusitis market intelligence report exhaustively examines the market value, share, demand, growth prospects, latest and historical trends, manufacturers, gross revenue collection, competitive terrain, market growth forecast, available products, and end-use applications.
Geographical Terrain of the Global Chronic Rhinosinusitis Market:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, France, the U.K, Russia, and Italy)
• Asia Pacific (China, Japan, Korea, India, and Southeast Asia)
• Latin America (Brazil, Argentina, Colombia, etc.)
• Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)
Access full Report Description, TOC, Table of Figure, Chart: https://www.emergenresearch.com/request-sample/74
Thank you for reading our report. For further details or to inquire about customization, please let us know, and we will offer you a report well-suited to your requirements.